BD delivered a strong Q4 beat on both revenue and EPS, with notable FCF acceleration. FY27 adjusted EPS guidance of $13.10-$13.30 implies ~3.1-4.7% growth from FY26 adjusted EPS of $12.70. The $19B U.S. manufacturing partnership with tariff relief is a strategic positive. Watch the December 10 Investor Day for further strategic and capital allocation details.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $213.55entry
- T+1 · 11d ago −0.78%α −1.09% · $211.88
- T+5 · 5d ago +1.01%α −2.28% · $215.71
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
BD reported Q4 FY2026 revenue of $5.274B (up 5.4% YoY, 5.6% FXN) and adjusted diluted EPS of $4.15, above the $4.07 consensus. FY26 cash from continuing operations rose 30% to $3.6B and free cash flow increased 42.5% to $2.9B. The company issued FY27 adjusted EPS guidance of $13.10-$13.30, implying low single-digit revenue growth.
Key Financial Metrics
Key Facts
- Q4 revenue $5.274B, +5.4% reported, +5.6% FXN vs prior year
- Q4 GAAP diluted EPS $2.52, adjusted diluted EPS $4.15
- Adjusted EPS $4.15 beat consensus of $4.07 (surprise +2.0%)
- Revenue $5.274B beat consensus of $5.11B (surprise +3.2%)
- FY26 revenue $19.457B, +4.9% reported, +3.9% FXN
- FY26 adjusted diluted EPS $12.70, vs prior guidance $12.52-$12.72
- FY26 cash from continuing ops $3.605B, +30.0%; free cash flow $2.933B, +42.5%
- FY27 adjusted EPS guidance $13.10-$13.30, revenue growth low single-digit
- Announced $19B U.S. manufacturing investment partnership with U.S. Government
Financial Impact
Q4 revenue beat by $164M (+3.2% vs consensus); adjusted EPS beat by $0.08 (+2.0% vs consensus); FY26 FCF $2.933B (+42.5% YoY)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Medical Essentials | $1.8B | +5.9% |
| Connected Care | $1.3B | +1.6% |
| BioPharma Systems | $748.0M | +6.5% |
| Interventional | $1.5B | +7.6% |
Risk Factors
- FY27 revenue guidance of low single-digit growth implies deceleration from FY26's 4.9% reported growth
- FY27 adjusted EPS guidance midpoint of $13.20 is only ~3.9% above FY26 adjusted EPS of $12.70
- Tariff and trade policy uncertainty remain, though the U.S. government partnership provides some relief
- Connected Care segment Q4 revenue growth was only 1.6% reported (2.1% FXN), with Medication Management Solutions declining 2.3% reported
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070511 |
| Document: bdx-20261105.htm | 0001628280-26-070511 |
| Document: 0001628280-26-070511-index-headers.html | 0001628280-26-070511 |
| Document: 0001628280-26-070511-index.html | 0001628280-26-070511 |
| Document: 0001628280-26-070511.txt | 0001628280-26-070511 |
| 8-K Data (Synthetic) | 0001628280-26-070511 |
Track record
17 reports on BDX
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $214.52 Now $216.47 +0.91% settles Nov 18
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
- Nov 5, 202611d ago Press Release Neutral 3/10 Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $209.19 to $214.52 Now $216.47 +3.48% ▲ +2.55% +3.46% vs SPY
- Oct 26, 202621d ago 144 Neutral 2/10 Entry $195.03 to $198.17 Now $216.47 +10.99% ▲ +1.61% +3.60% vs SPY
- Oct 6, 20265w ago Press Release Neutral 2/10 Entry $180.30 to $187.37 Now $216.47 +20.06% ▲ +3.92% +4.06% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $182.09 to $190.74 Now $216.47 +18.88% ▲ +4.75% +5.94% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $153.16 to $168.40 Now $216.47 +41.34% ▲ +9.95% +12.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers